Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.54 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.54 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.54 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.54 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4658952 | 0.87 | KDM4E (0.59) | KDM4ELMNAPOLBHDAC3HDAC4 | |
| SCHEMBL10244791 | 0.84 | HDAC3 (0.61) | KDM4ELMNAPOLBHDAC3HDAC4 | |
| SCHEMBL5727899 | 0.81 | KDM4E (0.46) | KDM4ELMNAPOLBMEN1KMT2A | |
| SCHEMBL29038565 | 0.81 | HDAC3 (0.67) | KDM4ELMNAHDAC3HDAC4HDAC1 | |
| SCHEMBL29038556 | 0.81 | HDAC3 (0.67) | KDM4ELMNAHDAC3HDAC4HDAC1 | |
| SCHEMBL4591337 | 0.81 | HDAC3 (0.58) | KDM4ELMNAPOLBHDAC3HDAC4 | |
| SCHEMBL4443806 | 0.81 | KDM4E (0.57) | KDM4ELMNAPOLBHDAC3HDAC4 | |
| SCHEMBL4591341 | 0.81 | HDAC3 (0.58) | KDM4ELMNAPOLBHDAC3HDAC4 | |
| SCHEMBL6343179 | 0.80 | KDM4E (0.56) | KDM4ELMNAPOLBHDAC3HDAC4 | |
| SCHEMBL5160575 | 0.80 | TSHR (0.50) | KDM4ELMNAPOLBHDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299069-B2 | 2-(2-oxoindoline-3-ylidene)methyl-5-(2-hydroxy-3-morpholin-4-yl-propyl)-6,7-dihydro-1H-pyrrol[3,2-C]pyridine-4(5H)-one compounds and use as protein kinase inhibitors | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2012-10-30 | — | — | US | claimed |
| EP-2179998-B1 | 2-(2-OXOINDOLINE-3-YLIDENE)METHYL-5-(2-HYDROXY-3-MORPHOLIN-4-YL -PROPYL)-6,7-DIHYDRO -1H- PYRROL[3,2-C]PYRIDINE-4(5H)-ONE COMPOUNDS AND USE AS PROTEIN KINASE INHIBITORS | JIANGSU HENGRUI MEDICINE CO (CN) | 2012-08-29 | — | — | EP | claimed |
| US-20100160317-A1 | 2-(2-OXOINDOLINE-3-YLIDENE)METHYL-5-(2-HYDROXY-3-MORPHOLIN-4-YL-PROPYL)-6,7-DIHYDRO-1H-PYRROL[3,2-C]PYRIDINE-4(5H)-ONE COMPOUNDS AND USE AS PROTEIN KINASE INHIBITORS | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2010-06-24 | — | — | US | claimed |
| EP-2179998-A1 | 2-(2-OXOINDOLINE-3-YLIDENE)METHYL-5-(2-HYDROXY-3-MORPHOLIN-4-YL -PROPYL)-6,7-DIHYDRO -1H- PYRROL[3,2-C]PYRIDINE-4(5H)-ONE COMPOUNDS AND USE AS PROTEIN KINASE INHIBITORS | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2010-04-28 | — | — | EP | claimed |
| US-20030139427-A1 | Bicyclic pyrimidinyl derivatives and methods of use thereof | OSI PHARMACEUTICALS INC. | 2003-07-24 | — | — | US | claimed |
| EP-0986539-A1 | DNA-BINDING PYRROLE AND IMIDAZOLE POLYAMIDE DERIVATIVES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2000-03-22 | — | — | EP | claimed |
| WO-1998049142-A1 | DNA-BINDING PYRROLE AND IMIDAZOLE POLYAMIDE DERIVATIVES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1998-11-05 | — | — | WO | claimed |
| US-8299069-B2 | 2-(2-oxoindoline-3-ylidene)methyl-5-(2-hydroxy-3-morpholin-4-yl-propyl)-6,7-dihydro-1H-pyrrol[3,2-C]pyridine-4(5H)-one compounds and use as protein kinase inhibitors | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2012-10-30 | — | — | US | disclosed |
| EP-2179998-B1 | 2-(2-OXOINDOLINE-3-YLIDENE)METHYL-5-(2-HYDROXY-3-MORPHOLIN-4-YL -PROPYL)-6,7-DIHYDRO -1H- PYRROL[3,2-C]PYRIDINE-4(5H)-ONE COMPOUNDS AND USE AS PROTEIN KINASE INHIBITORS | JIANGSU HENGRUI MEDICINE CO (CN) | 2012-08-29 | — | — | EP | disclosed |
| CN-102333889-A | Drug identification scheme for type II diabetes based on gene expression characteristics | VERVA PHARMACEUTICALS LTD | 2012-01-25 | — | — | CN | disclosed |
| US-20110318270-A1 | DRUG IDENTIFICATION PROTOCOL FOR TYPE 2 DIABETES BASED ON GENE EXPRESSION SIGNATURES | VERVA PHARMACEUTICALS LTD (AU) | 2011-12-29 | — | — | US | disclosed |
| US-RE42375-E1 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2011-05-17 | — | — | US | disclosed |
| US-20100160317-A1 | 2-(2-OXOINDOLINE-3-YLIDENE)METHYL-5-(2-HYDROXY-3-MORPHOLIN-4-YL-PROPYL)-6,7-DIHYDRO-1H-PYRROL[3,2-C]PYRIDINE-4(5H)-ONE COMPOUNDS AND USE AS PROTEIN KINASE INHIBITORS | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2010-06-24 | — | — | US | disclosed |
| EP-2179998-A1 | 2-(2-OXOINDOLINE-3-YLIDENE)METHYL-5-(2-HYDROXY-3-MORPHOLIN-4-YL -PROPYL)-6,7-DIHYDRO -1H- PYRROL[3,2-C]PYRIDINE-4(5H)-ONE COMPOUNDS AND USE AS PROTEIN KINASE INHIBITORS | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2010-04-28 | — | — | EP | disclosed |
| EP-2066627-A1 | NOVEL MINOR GROOVE BINDERS | The University of Strathclyde (GB) | 2009-06-10 | — | — | EP | disclosed |
| US-7368452-B2 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2008-05-06 | — | — | US | disclosed |
| WO-2008038018-A1 | NOVEL MINOR GROOVE BINDERS | UNIVERSITY OF STRATHCLYDE (GB) | 2008-04-03 | — | — | WO | disclosed |
| US-20070060510-A1 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2007-03-15 | — | — | US | disclosed |
| US-7176208-B2 | Prevent reproduction of hepatitis virus | ENANTA PHARMACEUTICALS, INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-20030139427-A1 | Bicyclic pyrimidinyl derivatives and methods of use thereof | OSI PHARMACEUTICALS INC. | 2003-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160317-A1 | 2-(2-OXOINDOLINE-3-YLIDENE)METHYL-5-(2-HYDROXY-3-MORPHOLIN-4-YL-PROPYL)-6,7-DIHYDRO-1H-PYRROL[3,2-C]PYRIDINE-4(5H)-ONE COMPOUNDS AND USE AS PROTEIN KINASE INHIBITORS | DMPK, MAP4K2, PLK2 | KDM4E 723/4885LMNA 2210/4885POLB 1836/4885 |
| US-20030139427-A1 | Bicyclic pyrimidinyl derivatives and methods of use thereof | ADORA2A, ADORA3, ADORA1 | KDM4E 4601/4885LMNA 1869/4885POLB 1303/4885 |
| US-20070060510-A1 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | PRSS1, SPINT2, HPN | KDM4E 765/4885LMNA 2324/4885POLB 3340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.